<DOC>
	<DOCNO>NCT00633789</DOCNO>
	<brief_summary>The purpose study determine gastric/esophageal , lung , pancreatic , bladder sarcoma patient show benefit brivanib treatment . Patients clearly , stay treatment . Those unclear randomize continue withdraw treatment determine whether benefit relate brivanib</brief_summary>
	<brief_title>Phase II Study Brivanib ( BMS-582664 ) Treat Multiple Tumor Types</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . Life expectancy least 3 month Diagnosis solid tumor unresectable approve effective therapy exist subject intolerable therapy . The initial enrollment focus nonsmall cell lung , gastric/esophageal adenocarcinoma , soft tissue sarcoma , transitional cell carcinoma , pancreatic cancer include ampulla Vater tumor Adequate tumor sample Adequate recovery ( baseline Grade 1 ) recent therapy . At least 1 week must elapse time minor surgery , least 8 week major surgery radiation therapy Subjects know brain metastasis . Subjects sign symptom suggestive brain metastasis eligible unless brain metastasis rule CT MRI Medical History Concurrent Diseases : History thromboembolic disease within last six month require therapeutic anticoagulation Subjects history poor wound heal non heal ulcer Uncontrolled significant cardiovascular disease Allergies Adverse Drug Reactions : History allergy brivanib drug class , related compound Prohibited Treatments and/or Therapies : Exposure investigational drug within 4 week enrollment Other concurrent chemotherapy , hormonal therapy , immunotherapy regimen radiotherapy , standard investigational . Subjects may continue receive hormone replacement therapy Prior exposure brivanib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>